Goodwin Procter recently advised client Unum Therapeutics on two significant transactions. On June 8, Goodwin advised Unum on its strategic collaboration and license agreement with Seattle Genetics (Nasdaq: SGEN) to develop and commercialize ACTR therapies for cancer. The firm also advised Unum on its $65 million Series B financing announced June 11. New Leaf Venture Partners, one of eight new investors, led the round; existing investors also participated in the oversubscribed funding.
Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. The company’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, recently entered Phase 1 clinical testing to assess safety and efficacy. The company is headquartered in Cambridge, Mass.
The Goodwin team advising Unum included Kingsley Taft, Danielle Lauzon, Sarah Solomon and Cheryl Campbell.
To learn more about Unum’s partnership with Seattle Genetics, please read the June 8 press release. Additional information regarding the company’s latest round of funding is available in Unum’s June 11 press release.